In Vitro Activity of Ceftazidime-Avibactam and Aztreonam-Avibactam against OXA-48-Carrying Enterobacteriaceae Isolated as Part of the International Network for Optimal Resistance Monitoring (INFORM) Global Surveillance Program from 2012 to 2015
- 1 December 2018
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 62 (12), e00592-18
- https://doi.org/10.1128/aac.00592-18
Abstract
Enterobacteriaceae producing the Ambler class D OXA-48 carbapenemase, combined with additional resistance mechanisms, such as permeability defects or cocarriage of class A, B, or C β-lactamases, can become highly resistant to most β-lactams currently in use, including carbapenems. A total of 45,872 Enterobacteriaceae clinical isolates collected in 39 countries as part of the International Network for Optimal Resistance Monitoring (INFORM) global surveillance study in 2012 to 2015 were tested for susceptibility to β-lactams and comparator agents using the Clinical and Laboratory Standards Institute broth microdilution methodology and screened for the presence of β-lactamases. The blaOXA-48 and blaOXA-48-like genes were detected in 333 isolates across 14 species of Enterobacteriaceae collected in 20 countries across the globe. Few agents tested were effective in vitro against the overall collection of OXA-48-producers (n = 265), with tigecycline (MIC90, 2 µg/ml; 92.5% susceptible), ceftazidime-avibactam (MIC90, 4 µg/ml; 92.5% susceptible), and aztreonam-avibactam (MIC90, 0.5 µg/ml; 99.6% of isolates with MIC ≤8 µg/ml) demonstrating the greatest activity. Similarly, colistin (MIC90, 1 µg/ml; 94.2% susceptible), tigecycline (MIC90, 2 µg/ml; 92.6% susceptible), ceftazidime-avibactam (MIC90, >128 µg/ml; 89.7% susceptible), and aztreonam-avibactam (MIC90, 4 µg/ml; 100% of isolates with MIC ≤8 µg/ml) were most active against OXA-48-like-positive isolates (n = 68). The in vitro activity of ceftazidime-avibactam was improved against the subset of metallo-β-lactamase (MBL)-negative, OXA-48- and OXA-48-like-positive isolates (99.2% and 100% susceptible, respectively). The data reported here support the continued investigation of ceftazidime-avibactam and aztreonam-avibactam for the treatment of infections caused by carbapenem-resistant Enterobacteriaceae carrying OXA-48 and OXA-48-like β-lactamases in combination with serine- or metallo-β-lactamases.Funding Information
- Pfizer
This publication has 75 references indexed in Scilit:
- Avibactam is a covalent, reversible, non–β-lactam β-lactamase inhibitorProceedings of the National Academy of Sciences of the United States of America, 2012
- Genetic Features of bla NDM-1 -Positive EnterobacteriaceaeAntimicrobial Agents and Chemotherapy, 2011
- Characterization of OXA-181, a Carbapenem-Hydrolyzing Class D β-Lactamase from Klebsiella pneumoniaeAntimicrobial Agents and Chemotherapy, 2011
- OXA-163, an OXA-48-Related Class D β-Lactamase with Extended Activity Toward Expanded-Spectrum CephalosporinsAntimicrobial Agents and Chemotherapy, 2011
- Activities of NXL104 Combinations with Ceftazidime and Aztreonam against Carbapenemase-Producing EnterobacteriaceaeAntimicrobial Agents and Chemotherapy, 2011
- Mechanistic Studies of the Inactivation of TEM-1 and P99 by NXL104, a Novel Non-β-Lactam β-Lactamase InhibitorAntimicrobial Agents and Chemotherapy, 2010
- High-Resolution Crystal Structure of the Subclass B3 Metallo-β-Lactamase BJP-1: Rational Basis for Substrate Specificity and Interaction with SulfonamidesAntimicrobial Agents and Chemotherapy, 2010
- Development of a set of multiplex PCR assays for the detection of genes encoding important β-lactamases in EnterobacteriaceaeJournal of Antimicrobial Chemotherapy, 2010
- In vitro activity of the -lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemasesJournal of Antimicrobial Chemotherapy, 2009
- Plasmid-Encoded Carbapenem-Hydrolyzing β-Lactamase OXA-48 in an Imipenem-Susceptible Klebsiella pneumoniae Strain from BelgiumAntimicrobial Agents and Chemotherapy, 2008